Pipeline and Research
Aiming at the intracellular pathways responsible for bacterial resistance, our approach is based on the identification and inactivation of bacterial resistance factors in relevant pathogens. One of the lead-compounds BV6481 already exhibited excellent characteristics in rendering multi-resistant Mycobacterium tuberculosis again sensitive to the classical antibiotic prodrug ethionamide. Based on the successful identification and application of BV6481 we are currently expanding our screening and compound portfolio to nosocomial bacterial strains (e.g. Pseudomonas aeruginosa, Enterococcus faecium or Acinetobacter baumannii) that contribute not only to the sky rocking costs of inpatient care, but also cause high number of casualties worldwide.